Home › Compare › TCRR vs O

TCRR vs O: Dividend Comparison 2026

TCRR yields 135.14% · O yields 5.28%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TCRR wins by $14.86M in total portfolio value
10 years
TCRR
TCRR
● Live price
135.14%
Share price
$1.48
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$14.90M
Annual income
$6,066,079.91
Full TCRR calculator →
O
Realty Income Corporation
● Live price
5.28%
Share price
$61.18
Annual div
$3.23
5Y div CAGR
15.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$34.2K
Annual income
$5,098.20
Full O calculator →

Portfolio growth — TCRR vs O

📍 TCRR pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTCRRO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TCRR + O cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TCRR pays
O pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TCRR
Annual income on $10K today (after 15% tax)
$11,486.49/yr
After 10yr DRIP, annual income (after tax)
$5,156,167.92/yr
O
Annual income on $10K today (after 15% tax)
$448.90/yr
After 10yr DRIP, annual income (after tax)
$4,333.47/yr
At 15% tax rate, TCRR beats the other by $5,151,834.45/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TCRR + O for your $10,000?

TCRR: 50%O: 50%
100% O50/50100% TCRR
Portfolio after 10yr
$7.47M
Annual income
$3,035,589.06/yr
Blended yield
40.66%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on O right now

TCRR
Analyst Ratings
2
Buy
6
Hold
1
Sell
Consensus: Hold
Price Target
$5.00
+237.8% upside vs current
Range: $5.00 — $5.00
Altman Z
-7.2
Piotroski
2/9
O
Analyst Ratings
13
Buy
18
Hold
3
Sell
Consensus: Hold
Price Target
$64.00
+4.6% upside vs current
Range: $60.00 — $69.00
Altman Z
1.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TCRR buys
0
O buys
0
No recent congressional trades found for TCRR or O in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTCRRO
Forward yield135.14% ✓5.28%
Annual dividend / share$2.00$3.23 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.1% ✓
Portfolio after 10y$14.90M$34.2K ✓
Annual income after 10y$6,066,079.91 ✓$5,098.20
Total dividends collected$13.68M$20.7K ✓
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusHoldHold
Analyst price target$5.00$64.00 ✓

Year-by-year: TCRR vs O ($10,000, DRIP)

YearTCRR PortfolioTCRR Income/yrO PortfolioO Income/yrGap
1← crossover$24,214$13,513.51$10,818$607.86+$13.4K → TCRR
2$56,489$30,580.34$11,786$741.30+$44.7K → TCRR
3$127,118$66,675.01$12,944$910.50+$114.2K → TCRR
4$276,241$140,224.56$14,343$1,127.28+$261.9K → TCRR
5$580,365$284,787.59$16,053$1,408.17+$564.3K → TCRR
6$1,180,170$559,178.96$18,167$1,776.65+$1.16M → TCRR
7$2,325,480$1,062,698.63$20,815$2,266.60+$2.30M → TCRR
8$4,445,281$1,957,016.59$24,179$2,927.66+$4.42M → TCRR
9$8,252,658$3,496,207.78$28,521$3,833.95+$8.22M → TCRR
10$14,896,424$6,066,079.91$34,218$5,098.20+$14.86M → TCRR

TCRR vs O: Complete Analysis 2026

TCRR — Stock

TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Full TCRR Calculator →

O — REIT

Realty Income, The Monthly Dividend Company, is an S&P 500 company dedicated to providing stockholders with dependable monthly income. The company is structured as a REIT, and its monthly dividends are supported by the cash flow from over 6,500 real estate properties owned under long-term lease agreements with our commercial clients. To date, the company has declared 608 consecutive common stock monthly dividends throughout its 52-year operating history and increased the dividend 109 times since Realty Income's public listing in 1994 (NYSE: O). The company is a member of the S&P 500 Dividend Aristocrats index. Additional information about the company can be obtained from the corporate website at www.realtyincome.com.

Full O Calculator →
📬

Get this TCRR vs O comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TCRR vs SCHDTCRR vs JEPITCRR vs KOTCRR vs MAINTCRR vs STAGTCRR vs ADCTCRR vs NNNTCRR vs VICI

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.